Condition: Advanced Lung Non-Small Cell Carcinoma · Metastatic Lung Non-Small Cell Carcinoma · Stage IV Lung Cancer AJCC v8 · Sponsor: Emory University
This phase Ib trial evaluates the best dose and side effects of MRX-2843 when given in combination with osimertinib in treating patients with EGFR gene mutant non-small cell lung cancer that has spread to other places in the body (advanced). MRX-2843 and osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
This description comes directly from the study's public registry record.
Conor Steuer, MD · 404-727-5658 · csteuer@emory.edu
Always discuss trial participation with your own doctor first.
| Emory University Hospital/Winship Cancer Institute | Atlanta, Georgia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04762199